NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

茲卡病毒檢驗的全球市場

Zika Virus Testing

出版商 Global Industry Analysts, Inc. 商品編碼 958891
出版日期 內容資訊 英文 185 Pages
商品交期: 最快1-2個工作天內
價格
茲卡病毒檢驗的全球市場 Zika Virus Testing
出版日期: 2021年04月01日內容資訊: 英文 185 Pages
簡介

全球茲卡病毒檢驗的市場規模在分析期間(2020年∼2027年)內預計將以6.4%的年複合成長率增長,從2020年的1億5,910萬美元到2027年達到2億4,560萬美元。本報告分析市場區隔之一的核酸增幅檢查 (NAAT) 部門在分析期間結束前預測將以6.8%的年率增長,達到1億2,970萬美元。

本報告提供全球茲卡病毒檢驗市場的相關調查,提供市場佔有率,趨勢和預測,成長要素,各地區的市場分析,競爭情形,主要企業的簡介等資訊。

調查對象企業範例

  • Biocan Diagnostics
  • Chembio Diagnostic Systems, Inc.
  • F. Hoffmann-La Roche AG
  • Hologic, Inc.
  • Quest Diagnostics, Inc.
  • SD Biosensor, Inc.

目錄

I. 簡介,調查手法,調查範圍

II. 摘要整理

  • 市場概要
    • 競爭的市場佔有率
    • 競爭的市場佔有率方案
    • Covid-19的影響和即將到來的全球景氣衰退
  • 主要企業
  • 趨勢與成長要素
  • 全球市場預測

III. 市場分析

  • 各地區市場分析
  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 西班牙
  • 俄羅斯
  • 其他歐洲
  • 亞太地區
  • 澳洲
  • 印度
  • 韓國
  • 其他亞太地區
  • 中南美
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他南美國家
  • 中東
  • 伊朗
  • 以色列
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 其他中東
  • 非洲

IV. 競爭

  • 簡介公司總數:47公司

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MCP15720

Abstract:

Global Zika Virus Testing Market to Reach $245.6 Million by 2027

Amid the COVID-19 crisis, the global market for Zika Virus Testing estimated at US$159.1 Million in the year 2020, is projected to reach a revised size of US$245.6 Million by 2027, growing at aCAGR of 6.4% over the period 2020-2027. Nucleic Acid Amplification Testing (NAAT), one of the segments analyzed in the report, is projected to record 6.8% CAGR and reach US$129.7 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Serological Testing segment is readjusted to a revised 6% CAGR for the next 7-year period.

The U.S. Market is Estimated at $43.1 Million, While China is Forecast to Grow at 9.8% CAGR

The Zika Virus Testing market in the U.S. is estimated at US$43.1 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$53.1 Million by the year 2027 trailing a CAGR of 9.8% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.5% and 5.8% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.1% CAGR.

Select Competitors (Total 47 Featured) -

  • Biocan Diagnostics
  • Chembio Diagnostic Systems, Inc.
  • F. Hoffmann-La Roche AG
  • Hologic, Inc.
  • Quest Diagnostics, Inc.
  • SD Biosensor, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Zika Virus Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
    • TABLE 2: World Historic Review for Zika Virus Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
    • TABLE 3: World 15-Year Perspective for Zika Virus Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2020 & 2027
    • TABLE 4: World Current & Future Analysis for Nucleic Acid Amplification Testing (NAAT) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
    • TABLE 5: World Historic Review for Nucleic Acid Amplification Testing (NAAT) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
    • TABLE 6: World 15-Year Perspective for Nucleic Acid Amplification Testing (NAAT) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 7: World Current & Future Analysis for Serological Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
    • TABLE 8: World Historic Review for Serological Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
    • TABLE 9: World 15-Year Perspective for Serological Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • TABLE 10: USA Current & Future Analysis for Zika Virus Testing by Segment - Nucleic Acid Amplification Testing (NAAT) and Serological Testing - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 11: USA Historic Review for Zika Virus Testing by Segment - Nucleic Acid Amplification Testing (NAAT) and Serological Testing Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
    • TABLE 12: USA 15-Year Perspective for Zika Virus Testing by Segment - Percentage Breakdown of Value Sales for Nucleic Acid Amplification Testing (NAAT) and Serological Testing for the Years 2012, 2020 & 2027
  • CANADA
    • TABLE 13: Canada Current & Future Analysis for Zika Virus Testing by Segment - Nucleic Acid Amplification Testing (NAAT) and Serological Testing - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 14: Canada Historic Review for Zika Virus Testing by Segment - Nucleic Acid Amplification Testing (NAAT) and Serological Testing Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
    • TABLE 15: Canada 15-Year Perspective for Zika Virus Testing by Segment - Percentage Breakdown of Value Sales for Nucleic Acid Amplification Testing (NAAT) and Serological Testing for the Years 2012, 2020 & 2027
  • JAPAN
    • TABLE 16: Japan Current & Future Analysis for Zika Virus Testing by Segment - Nucleic Acid Amplification Testing (NAAT) and Serological Testing - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 17: Japan Historic Review for Zika Virus Testing by Segment - Nucleic Acid Amplification Testing (NAAT) and Serological Testing Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
    • TABLE 18: Japan 15-Year Perspective for Zika Virus Testing by Segment - Percentage Breakdown of Value Sales for Nucleic Acid Amplification Testing (NAAT) and Serological Testing for the Years 2012, 2020 & 2027
  • CHINA
    • TABLE 19: China Current & Future Analysis for Zika Virus Testing by Segment - Nucleic Acid Amplification Testing (NAAT) and Serological Testing - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 20: China Historic Review for Zika Virus Testing by Segment - Nucleic Acid Amplification Testing (NAAT) and Serological Testing Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
    • TABLE 21: China 15-Year Perspective for Zika Virus Testing by Segment - Percentage Breakdown of Value Sales for Nucleic Acid Amplification Testing (NAAT) and Serological Testing for the Years 2012, 2020 & 2027
  • EUROPE
    • TABLE 22: Europe Current & Future Analysis for Zika Virus Testing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
    • TABLE 23: Europe Historic Review for Zika Virus Testing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
    • TABLE 24: Europe 15-Year Perspective for Zika Virus Testing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2020 & 2027
    • TABLE 25: Europe Current & Future Analysis for Zika Virus Testing by Segment - Nucleic Acid Amplification Testing (NAAT) and Serological Testing - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 26: Europe Historic Review for Zika Virus Testing by Segment - Nucleic Acid Amplification Testing (NAAT) and Serological Testing Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
    • TABLE 27: Europe 15-Year Perspective for Zika Virus Testing by Segment - Percentage Breakdown of Value Sales for Nucleic Acid Amplification Testing (NAAT) and Serological Testing for the Years 2012, 2020 & 2027
  • FRANCE
    • TABLE 28: France Current & Future Analysis for Zika Virus Testing by Segment - Nucleic Acid Amplification Testing (NAAT) and Serological Testing - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 29: France Historic Review for Zika Virus Testing by Segment - Nucleic Acid Amplification Testing (NAAT) and Serological Testing Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
    • TABLE 30: France 15-Year Perspective for Zika Virus Testing by Segment - Percentage Breakdown of Value Sales for Nucleic Acid Amplification Testing (NAAT) and Serological Testing for the Years 2012, 2020 & 2027
  • GERMANY
    • TABLE 31: Germany Current & Future Analysis for Zika Virus Testing by Segment - Nucleic Acid Amplification Testing (NAAT) and Serological Testing - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 32: Germany Historic Review for Zika Virus Testing by Segment - Nucleic Acid Amplification Testing (NAAT) and Serological Testing Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
    • TABLE 33: Germany 15-Year Perspective for Zika Virus Testing by Segment - Percentage Breakdown of Value Sales for Nucleic Acid Amplification Testing (NAAT) and Serological Testing for the Years 2012, 2020 & 2027
  • ITALY
    • TABLE 34: Italy Current & Future Analysis for Zika Virus Testing by Segment - Nucleic Acid Amplification Testing (NAAT) and Serological Testing - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 35: Italy Historic Review for Zika Virus Testing by Segment - Nucleic Acid Amplification Testing (NAAT) and Serological Testing Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
    • TABLE 36: Italy 15-Year Perspective for Zika Virus Testing by Segment - Percentage Breakdown of Value Sales for Nucleic Acid Amplification Testing (NAAT) and Serological Testing for the Years 2012, 2020 & 2027
  • UNITED KINGDOM
    • TABLE 37: UK Current & Future Analysis for Zika Virus Testing by Segment - Nucleic Acid Amplification Testing (NAAT) and Serological Testing - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 38: UK Historic Review for Zika Virus Testing by Segment - Nucleic Acid Amplification Testing (NAAT) and Serological Testing Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
    • TABLE 39: UK 15-Year Perspective for Zika Virus Testing by Segment - Percentage Breakdown of Value Sales for Nucleic Acid Amplification Testing (NAAT) and Serological Testing for the Years 2012, 2020 & 2027
  • SPAIN
    • TABLE 40: Spain Current & Future Analysis for Zika Virus Testing by Segment - Nucleic Acid Amplification Testing (NAAT) and Serological Testing - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 41: Spain Historic Review for Zika Virus Testing by Segment - Nucleic Acid Amplification Testing (NAAT) and Serological Testing Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
    • TABLE 42: Spain 15-Year Perspective for Zika Virus Testing by Segment - Percentage Breakdown of Value Sales for Nucleic Acid Amplification Testing (NAAT) and Serological Testing for the Years 2012, 2020 & 2027
  • RUSSIA
    • TABLE 43: Russia Current & Future Analysis for Zika Virus Testing by Segment - Nucleic Acid Amplification Testing (NAAT) and Serological Testing - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 44: Russia Historic Review for Zika Virus Testing by Segment - Nucleic Acid Amplification Testing (NAAT) and Serological Testing Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
    • TABLE 45: Russia 15-Year Perspective for Zika Virus Testing by Segment - Percentage Breakdown of Value Sales for Nucleic Acid Amplification Testing (NAAT) and Serological Testing for the Years 2012, 2020 & 2027
  • REST OF EUROPE
    • TABLE 46: Rest of Europe Current & Future Analysis for Zika Virus Testing by Segment - Nucleic Acid Amplification Testing (NAAT) and Serological Testing - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 47: Rest of Europe Historic Review for Zika Virus Testing by Segment - Nucleic Acid Amplification Testing (NAAT) and Serological Testing Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
    • TABLE 48: Rest of Europe 15-Year Perspective for Zika Virus Testing by Segment - Percentage Breakdown of Value Sales for Nucleic Acid Amplification Testing (NAAT) and Serological Testing for the Years 2012, 2020 & 2027
  • ASIA-PACIFIC
    • TABLE 49: Asia-Pacific Current & Future Analysis for Zika Virus Testing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
    • TABLE 50: Asia-Pacific Historic Review for Zika Virus Testing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
    • TABLE 51: Asia-Pacific 15-Year Perspective for Zika Virus Testing by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2020 & 2027
    • TABLE 52: Asia-Pacific Current & Future Analysis for Zika Virus Testing by Segment - Nucleic Acid Amplification Testing (NAAT) and Serological Testing - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 53: Asia-Pacific Historic Review for Zika Virus Testing by Segment - Nucleic Acid Amplification Testing (NAAT) and Serological Testing Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
    • TABLE 54: Asia-Pacific 15-Year Perspective for Zika Virus Testing by Segment - Percentage Breakdown of Value Sales for Nucleic Acid Amplification Testing (NAAT) and Serological Testing for the Years 2012, 2020 & 2027
  • AUSTRALIA
    • TABLE 55: Australia Current & Future Analysis for Zika Virus Testing by Segment - Nucleic Acid Amplification Testing (NAAT) and Serological Testing - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 56: Australia Historic Review for Zika Virus Testing by Segment - Nucleic Acid Amplification Testing (NAAT) and Serological Testing Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
    • TABLE 57: Australia 15-Year Perspective for Zika Virus Testing by Segment - Percentage Breakdown of Value Sales for Nucleic Acid Amplification Testing (NAAT) and Serological Testing for the Years 2012, 2020 & 2027
  • INDIA
    • TABLE 58: India Current & Future Analysis for Zika Virus Testing by Segment - Nucleic Acid Amplification Testing (NAAT) and Serological Testing - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 59: India Historic Review for Zika Virus Testing by Segment - Nucleic Acid Amplification Testing (NAAT) and Serological Testing Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
    • TABLE 60: India 15-Year Perspective for Zika Virus Testing by Segment - Percentage Breakdown of Value Sales for Nucleic Acid Amplification Testing (NAAT) and Serological Testing for the Years 2012, 2020 & 2027
  • SOUTH KOREA
    • TABLE 61: South Korea Current & Future Analysis for Zika Virus Testing by Segment - Nucleic Acid Amplification Testing (NAAT) and Serological Testing - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 62: South Korea Historic Review for Zika Virus Testing by Segment - Nucleic Acid Amplification Testing (NAAT) and Serological Testing Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
    • TABLE 63: South Korea 15-Year Perspective for Zika Virus Testing by Segment - Percentage Breakdown of Value Sales for Nucleic Acid Amplification Testing (NAAT) and Serological Testing for the Years 2012, 2020 & 2027
  • REST OF ASIA-PACIFIC
    • TABLE 64: Rest of Asia-Pacific Current & Future Analysis for Zika Virus Testing by Segment - Nucleic Acid Amplification Testing (NAAT) and Serological Testing - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 65: Rest of Asia-Pacific Historic Review for Zika Virus Testing by Segment - Nucleic Acid Amplification Testing (NAAT) and Serological Testing Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
    • TABLE 66: Rest of Asia-Pacific 15-Year Perspective for Zika Virus Testing by Segment - Percentage Breakdown of Value Sales for Nucleic Acid Amplification Testing (NAAT) and Serological Testing for the Years 2012, 2020 & 2027
  • LATIN AMERICA
    • TABLE 67: Latin America Current & Future Analysis for Zika Virus Testing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
    • TABLE 68: Latin America Historic Review for Zika Virus Testing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
    • TABLE 69: Latin America 15-Year Perspective for Zika Virus Testing by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2020 & 2027
    • TABLE 70: Latin America Current & Future Analysis for Zika Virus Testing by Segment - Nucleic Acid Amplification Testing (NAAT) and Serological Testing - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 71: Latin America Historic Review for Zika Virus Testing by Segment - Nucleic Acid Amplification Testing (NAAT) and Serological Testing Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
    • TABLE 72: Latin America 15-Year Perspective for Zika Virus Testing by Segment - Percentage Breakdown of Value Sales for Nucleic Acid Amplification Testing (NAAT) and Serological Testing for the Years 2012, 2020 & 2027
  • ARGENTINA
    • TABLE 73: Argentina Current & Future Analysis for Zika Virus Testing by Segment - Nucleic Acid Amplification Testing (NAAT) and Serological Testing - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 74: Argentina Historic Review for Zika Virus Testing by Segment - Nucleic Acid Amplification Testing (NAAT) and Serological Testing Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
    • TABLE 75: Argentina 15-Year Perspective for Zika Virus Testing by Segment - Percentage Breakdown of Value Sales for Nucleic Acid Amplification Testing (NAAT) and Serological Testing for the Years 2012, 2020 & 2027
  • BRAZIL
    • TABLE 76: Brazil Current & Future Analysis for Zika Virus Testing by Segment - Nucleic Acid Amplification Testing (NAAT) and Serological Testing - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 77: Brazil Historic Review for Zika Virus Testing by Segment - Nucleic Acid Amplification Testing (NAAT) and Serological Testing Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
    • TABLE 78: Brazil 15-Year Perspective for Zika Virus Testing by Segment - Percentage Breakdown of Value Sales for Nucleic Acid Amplification Testing (NAAT) and Serological Testing for the Years 2012, 2020 & 2027
  • MEXICO
    • TABLE 79: Mexico Current & Future Analysis for Zika Virus Testing by Segment - Nucleic Acid Amplification Testing (NAAT) and Serological Testing - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 80: Mexico Historic Review for Zika Virus Testing by Segment - Nucleic Acid Amplification Testing (NAAT) and Serological Testing Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
    • TABLE 81: Mexico 15-Year Perspective for Zika Virus Testing by Segment - Percentage Breakdown of Value Sales for Nucleic Acid Amplification Testing (NAAT) and Serological Testing for the Years 2012, 2020 & 2027
  • REST OF LATIN AMERICA
    • TABLE 82: Rest of Latin America Current & Future Analysis for Zika Virus Testing by Segment - Nucleic Acid Amplification Testing (NAAT) and Serological Testing - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 83: Rest of Latin America Historic Review for Zika Virus Testing by Segment - Nucleic Acid Amplification Testing (NAAT) and Serological Testing Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
    • TABLE 84: Rest of Latin America 15-Year Perspective for Zika Virus Testing by Segment - Percentage Breakdown of Value Sales for Nucleic Acid Amplification Testing (NAAT) and Serological Testing for the Years 2012, 2020 & 2027
  • MIDDLE EAST
    • TABLE 85: Middle East Current & Future Analysis for Zika Virus Testing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
    • TABLE 86: Middle East Historic Review for Zika Virus Testing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
    • TABLE 87: Middle East 15-Year Perspective for Zika Virus Testing by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2020 & 2027
    • TABLE 88: Middle East Current & Future Analysis for Zika Virus Testing by Segment - Nucleic Acid Amplification Testing (NAAT) and Serological Testing - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 89: Middle East Historic Review for Zika Virus Testing by Segment - Nucleic Acid Amplification Testing (NAAT) and Serological Testing Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
    • TABLE 90: Middle East 15-Year Perspective for Zika Virus Testing by Segment - Percentage Breakdown of Value Sales for Nucleic Acid Amplification Testing (NAAT) and Serological Testing for the Years 2012, 2020 & 2027
  • IRAN
    • TABLE 91: Iran Current & Future Analysis for Zika Virus Testing by Segment - Nucleic Acid Amplification Testing (NAAT) and Serological Testing - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 92: Iran Historic Review for Zika Virus Testing by Segment - Nucleic Acid Amplification Testing (NAAT) and Serological Testing Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
    • TABLE 93: Iran 15-Year Perspective for Zika Virus Testing by Segment - Percentage Breakdown of Value Sales for Nucleic Acid Amplification Testing (NAAT) and Serological Testing for the Years 2012, 2020 & 2027
  • ISRAEL
    • TABLE 94: Israel Current & Future Analysis for Zika Virus Testing by Segment - Nucleic Acid Amplification Testing (NAAT) and Serological Testing - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 95: Israel Historic Review for Zika Virus Testing by Segment - Nucleic Acid Amplification Testing (NAAT) and Serological Testing Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
    • TABLE 96: Israel 15-Year Perspective for Zika Virus Testing by Segment - Percentage Breakdown of Value Sales for Nucleic Acid Amplification Testing (NAAT) and Serological Testing for the Years 2012, 2020 & 2027
  • SAUDI ARABIA
    • TABLE 97: Saudi Arabia Current & Future Analysis for Zika Virus Testing by Segment - Nucleic Acid Amplification Testing (NAAT) and Serological Testing - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 98: Saudi Arabia Historic Review for Zika Virus Testing by Segment - Nucleic Acid Amplification Testing (NAAT) and Serological Testing Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
    • TABLE 99: Saudi Arabia 15-Year Perspective for Zika Virus Testing by Segment - Percentage Breakdown of Value Sales for Nucleic Acid Amplification Testing (NAAT) and Serological Testing for the Years 2012, 2020 & 2027
  • UNITED ARAB EMIRATES
    • TABLE 100: UAE Current & Future Analysis for Zika Virus Testing by Segment - Nucleic Acid Amplification Testing (NAAT) and Serological Testing - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 101: UAE Historic Review for Zika Virus Testing by Segment - Nucleic Acid Amplification Testing (NAAT) and Serological Testing Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
    • TABLE 102: UAE 15-Year Perspective for Zika Virus Testing by Segment - Percentage Breakdown of Value Sales for Nucleic Acid Amplification Testing (NAAT) and Serological Testing for the Years 2012, 2020 & 2027
  • REST OF MIDDLE EAST
    • TABLE 103: Rest of Middle East Current & Future Analysis for Zika Virus Testing by Segment - Nucleic Acid Amplification Testing (NAAT) and Serological Testing - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 104: Rest of Middle East Historic Review for Zika Virus Testing by Segment - Nucleic Acid Amplification Testing (NAAT) and Serological Testing Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
    • TABLE 105: Rest of Middle East 15-Year Perspective for Zika Virus Testing by Segment - Percentage Breakdown of Value Sales for Nucleic Acid Amplification Testing (NAAT) and Serological Testing for the Years 2012, 2020 & 2027
  • AFRICA
    • TABLE 106: Africa Current & Future Analysis for Zika Virus Testing by Segment - Nucleic Acid Amplification Testing (NAAT) and Serological Testing - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 107: Africa Historic Review for Zika Virus Testing by Segment - Nucleic Acid Amplification Testing (NAAT) and Serological Testing Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR
    • TABLE 108: Africa 15-Year Perspective for Zika Virus Testing by Segment - Percentage Breakdown of Value Sales for Nucleic Acid Amplification Testing (NAAT) and Serological Testing for the Years 2012, 2020 & 2027

IV. COMPETITION

  • Total Companies Profiled: 47